a PRagmatic Observational Study of Congestion proFILes in patiEnts With Acute Heart Failure

NCT ID: NCT06587854

Last Updated: 2025-09-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

270 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-01

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational is to study the prevalence of distinct congestion phenotypes and study their association with response to therapy and outcomes in acute heart failure patients. The main question\[s\] it aims to answer \[is/are\]:

* Primary objective: to study the prevalence of distinct congestion phenotypes
* Other objectives (including):

* Response to therapy as assessed by

* Natriuresis after 24 hours
* Rehospitalization and/or deats after 6 months
* Length of hospital stay
* Congestion at discharge
* Changes in filling pressures over time
* Relationship between liver stiffness, as assessed with Fibroscan and congestion
* Substudy: glycosaminoglycan netword and endothial glycocalyx

Participants will undergo several extra study related measurements:

* Assessment of filling pressures with ultrasound
* Ultrasound investigation of the lungs and kidneys
* Fibroscan of the liver
* Sidestream darkfield imaging sublingual
* As part of substudy GLYCO-AHF: skin biopsy to determine glycocalyx, as well as salt and water content.
* As part of substudy PREACH-AHF: the effects of peripheral venous congestion and endothelial dysfunction on a large screen of plasma proteins

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: to study the prevalence of distinct congestion phenotypes and investigate their association with response to therapy and outcomes in acute heart failure patients.

Study design: Observational, prospective study

Study population: 270 patients admitted with the primary diagnosis of acute heart failure requiring intravenous loop diuretics.

Main study parameters/endpoints:

To identify distinct congestion phenotypes and study their association with response to therapy and outcomes

Secondary outcomes: total natriuresis after 24 hours, and first occurrence of all-cause mortality or heart failure rehospitalisation at 6 months Exploratory outcomes include: length of hospital stay, congestion at discharge and changes in filling pressures over time. Furthermore, as part of the GLYCO-AHF substudy: the expression of glycosaminoglycans and, as part of the PREACH-AHF substudy: the effects of peripheral venous congestion and endothelial dysfunction on a large screen of plasma proteins.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able and willing to give written informed consent
* Age ≥ 18 years
* Male or female
* Primary diagnosis of acute heart failure at presentation, with signs and symptoms of tissue decongestion. Diagnosis is based on the criteria in the ESC HF guidelines (1)
* Requirement of intravenous loop diuretics

Exclusion Criteria

* Patients with severe kidney dysfunction (in need for ultrafiltration or dialysis)
* Previous participation in this study
* Inability to follow instructions
* Dyspnoea or oedema primarily due to non-cardiac causes
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medical Center Groningen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jozine ter Maaten

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UMCG

Groningen, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jozine M. ter Maaten, MD, PhD

Role: CONTACT

+31503616161

Lara E.E.C. Zonneveld, MD

Role: CONTACT

+31503616161

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lara E.E.C. Zonneveld, MD

Role: primary

+31503616161

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20486

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Acute Congestive Heart Failure
NCT01885403 UNKNOWN NA
Provocative Tests for HFpEF
NCT06309550 RECRUITING
Heart Failure Patients Registry
NCT04709263 COMPLETED